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Abstract 
Hepatocellular carcinoma (HCC) is the most frequent 
form of liver cancer and the third most common cause 
of cancer-related death in the world. The main risk 
factor worldwide for this type of malignancy is chronic 
hepatitis caused by hepatitis B virus and hepatitis C virus 
infections. Advances in early detection and treatment 
have improved life expectancy of patients with HCC. 
However, this disorder remains as a disease with poor 
prognosis. In fact, epidemiological studies have revealed 
that there is an 8-mo median survival rate in patients, 
approximately 20% of whom survive one year while 
only 5% remain alive after three years. Additionally, 
HCC is particularly difficult to treat because of its high 
recurrence rate, and its resistance to conventional 
chemotherapy is due, among other mechanisms, to 
several members of the ATP-Binding Cassette protein 
family involved in drug transport being overexpressed. 
Fortunately, there is evidence that these patients may 
benefit from alternative molecular-targeted therapies. 
This manuscript intends to provide further insight into 
the etiology and molecular mechanisms related to HCC 
development and the latest therapeutic approaches to 
treat this malignancy. The development of effective 
delivery systems of antitumor drugs able to target the 
liver parenchyma is also assessed. Finally, the prospects 
in the development of more efficient drug therapies to 
overcome multidrug resistance are also examined.
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Core tip: Hepatocellular carcinoma (HCC) is the most 
frequent malignancy of the liver. Despite the advances 
in early detection and treatment, this disorder still has 
a poor prognosis. This manuscript reviews the ongoing 
knowledge regarding the etiology and molecular 
mechanisms implicated in HCC development and the 
therapeutic strategies for the management of this 
malignancy. Finally, the development of effective delivery 
systems of antitumor drugs able to target the liver 
parenchyma as well as the prospects in the development 
of a more efficient drug therapy to overcome multidrug 
resistance are also examined.
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INTRODUCTION
Liver cancer, which is ranked fifth in frequency of 
occurrence worldwide and third in cancer mortality, is one 
of the most frequent types of cancer[1]. Hepatocellular 
carcinoma (HCC) represents 85%-90% of primary liver 
cancers and is the main subtype in terms of histologic 
origin. Its clinical course is aggressive, while frequent 
recurrence and metastasis are often associated with 
this malignancy. It is characterized by late presentation, 
fast progression, limited response to therapy and a 
very poor survival rate (6%)[2]. Asia and Africa are the 
countries where HCC is more prevalent; however, there 
has been a rising trend of HCC in Western countries[3]. 
Chronic liver diseases, such as chronic hepatitis B (CHB) 
and CHC[4] are among the major risk factors for HCC 
development. Other common causes leading to the 
development of this malignancy are: hemochromatosis, 
fatty liver diseases unrelated to alcohol consumption 
(non-alcoholic fatty liver disease), primary biliary 
cirrhosis, primary sclerosing cholangitis, autoimmune 
hepatitis, excessive alcohol use, ingestion of food 
contaminated with aflatoxin, vinyl chloride, and use of 
radioactive agents such as thorotras[5,6]. 
The development of HCC involves several steps of 
a complex process characterized by both genetic and 
epigenetic changes that may activate cellular oncogenes, 
inactivate tumor suppressor genes and/or dysregulate 
multiple cell signal transduction pathways, such as the 
Wnt/β-catenin, the Ras-Raf-mitogen-activated protein 
kinase (MAPK), the phosphoinositide 3-kinase (PI3K)/
Akt/mammalian target of rapamycin (mTOR) and the 
transforming growth factor-β (TGF-β) pathways[7-9]. 
Several potentially curative or palliative approaches 
to the treatment of HCC are available. The surgical 
approaches that are most commonly chosen are: 
surgical resection and orthotopic liver transplantation. 
However, preserved or adequate liver function is an 
essential criterion for surgical resection. In this regard, 
this surgical approach is not a feasible option for HCC 
patients[10] when the tumor is at an advanced stage, 
or is located in close proximity to important hepatic 
vessels within the liver preventing a negative-margin 
resection, or when there are tumors at multiple sites 
or there is inadequate remaining hepatic function. 
Furthermore, about 17%-69% of patients suffer from 
recurrence, thus limiting their long-term survival at 5 
years postoperatively[11]. Orthotopic liver transplantation 
is considered to be the only curative solution for HCC 
that cannot be surgically removed. Candidates for this 
procedure are those patients having solitary HCCs of 
less than 5 cm in size or up to three nodules, each 
smaller than 3 cm[12,13]. Nevertheless, this procedure 
has limited availability due to the great difficulty in 
finding organ donors[10]. 
Non-surgical therapeutic approaches for HCC 
such as radiofrequency ablation (RFA), percutaneous 
ethanol injection (PEI), transarterial embolization 
(TAE) and transarterial chemoembolization (TACE) 
are other therapeutic tools used to substitute first-
line procedures; however, the probable course of the 
disease for the patients undergoing such procedures is 
still bleak. The annual recurrence rate is approximately 
15%-20%, reaching 80%-90% within the 5-year post-
treatment period[14,15]. A research study confirms that 
so far there are no adjuvant therapeutic postoperative 
regimens to successfully treat HCC.
A clinical investigation indicates that none of 
the adjuvant therapies is particularly effective in 
the treatment of HCC after surgery[16]. Systemic 
chemotherapy with doxorubicin, immunotherapy using 
interferon and hormonal therapy with tamoxifen, 
on the other hand, yielded poor results, with no 
significant survival benefits compared with symptomatic 
management[17-19]. One important limitation in the 
chemotherapy for HCC is the emergence of multidrug 
resistance (MDR) to conventional anti-tumoral 
agents[20]. This phenotype is commonly related to cancer 
cells that are able to overexpress drug transporter 
proteins belonging to the ATP-binding cassette (ABC) 
superfamily of proteins that move drugs out of cells, 
such as P-glycoprotein (P-gp), the multidrug resistance-
associated proteins (MRPs) and the breast cancer 
resistance protein (BCRP)[21]. Additionally, current anti-
tumoral drugs used in HCC treatment, also promote 
significant toxicities in other non-target organs affecting 
patient compliance and adherence to these therapeutic 
regimens[22]. Enhanced delivery[23] of these commercially 
available anti-cancer agents to liver parenchyma may 
provide an opportunity to selectively improve the 
efficacy of the current therapies and simultaneously 
reduce the adverse effects that often lead to treatment 
failure. 
Up to now, no succesful systemic chemotherapy 
for patients with advanced and unresectable HCC 
is available. However, on November 16, 2007, the 
federal drug administration (FDA; United States) had 
approved sorafenib tosylate (Nexavar® tablets, made 
by Bayer Pharmaceuticals Corp.), as “a small molecule 
Raf kinase and VEGF receptor kinase inhibitor, for the 
treatment of patients with unresectable hepatocellular 
carcinoma (HCC)”. Unfortunately, this promising 
treatment has demonstrated limited survival benefits 
with very low response rates[24,25]. Therefore, new 
approaches are urgently needed for: (1) improving the 
activity of prevailing antichemotherapeutic agents by 
targeting them to the liver using drug delivery systems 
designed with targeting moieties; (2) overcoming 
MDR by sensitizing tumor cells to conventional 
chemotherapeutics; and (3) improving the prognosis 
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of HCC by further development of the latest molecular 
targeting agents, such as sorafenib and rapamycin 
which - although limited - at present are deemed to be 
the most effective agents for managing unresectable 
HCC.
In this analysis we review the available information 
regarding the latest pharmacotherapy options for 
the treatment of patients suffering from advanced 
HCC, including molecular targeting agents. Prospects 
regarding a more effective pharmacotherapy for liver 
targeting and avoiding/preventing multidrug resistance 
in cancer cells are also addressed.
CURRENT THERAPIES FOR HCC
Unfortunately, owing to the asymptomatic nature of 
early HCC, in a majority of patients, HCC is usually 
diagnosed at an advanced stage, when most potentially 
curative therapies such as surgical resection, orthotopic 
liver transplantation and local ablation display a low 
efficacy. Moreover, in 60% to 80% of patients with liver 
cancer, the treatment is complicated by underlying 
liver cirrhosis and hepatic dysfunction[26]. In these 
advanced stages, systemic treatments are commonly 
used; however, they are also minimally effective, have 
severe side effects, develop high drug resistance, and 
most importantly, patient survival is not improved. 
HCC is rarely amenable to radiotherapy, leaving this 
disease with no effective therapeutic options and a very 
poor prognosis[27]. Through better understanding the 
molecular basis of hepatocarcinogenesis (e.g., signal 
pathways and molecular alterations that promotes 
tumor growth and cell survival), new treatment modalities 
have recently emerged including molecular targeted 
therapy and gene therapy, such as antisense gene 
targeting. 
Surgical therapies
At present, surgical resection and orthotopic liver 
transplantation offer the only chance for long-term cure 
of patients suffering from HCC. Surgical resection is an 
effective treatment for those patients with HCC that is 
not associated with liver cirrhosis or in patients whose 
hepatic function is well compensated. This means, 
that surgical resection is an option for only a small 
proportion of patients, less than 18%, since underlying 
chronic liver disease or cirrhosis accounts for about 
85%-90% of HCC patients[28]. Thus, both tumor extent 
and hepatic function must be evaluated pre-operatively 
to avoid hepatic failure following resection, which is 
usually a fatal condition possibly requiring urgent 
liver transplantation. There is a 5-year post-operative 
survival rate of 40%-70% of duly selected candidates 
for liver resection; however, relapse takes place in near 
70%, especially in patients with cirrhosis[29]. For this 
reason, orthotopic liver transplantation is considered 
to be the best choice for those patients suffering from 
HCC and cirrhosis, showing 5-year post-transplant 
survival rates of 65%-80% among well-selected 
candidates. Nevertheless, there is a limitation as to 
the use of this procedure, since the shortage of human 
donors is an unfortunate event these days[10]. Due to 
the strictness of Milan criteria regarding transplantation 
and the restrictions in finding available donors, 
scientists are now devoted to exploring other therapies 
for managing the disease in order to provide a solution 
for the disadvantages arising from transplantation or 
surgical resection[30]. 
Non-surgical therapies
Locoregional therapies: Percutaneous treatments: 
Percutaneous ablation (PA) is now the first alternative 
treatment when resection or orthotopic liver trans-
plantation has been ruled out in patients suffering 
from early-stage HCC. PA can be thermal or chemical. 
The thermal ablation procedure destroys cancer cells 
by cryoablation or by heat using lasers, high intensity 
focused ultrasound, microwaves or radiotherapy. 
Chemical ablation consists on cancer cells destruction by 
injecting chemicals - e.g., ethanol/acetic acid- introduced 
into the tumor mass by means of a very fine needle[10]. 
The ablative method as a treatment of choice will be 
based on the size of the tumor. 
PEI was introduced in the 1980’s, nowadays being 
the most prevalent kind of PA for treating HCC. Cohort 
studies and retrospective series analysis have shown 
that a five - year survival might be possible in 50%-80% 
of patients having a single tumor smaller than 5 cm in 
size or up to three nodules, lesser than 3 cm in size[31]. 
The main drawback of PEI is the high local recurrence 
rate (33%-43% at three years)[32]. RFA (radiofrequency 
ablation) is another ablative procedure initially outlined 
by Rossi et al[33], in 1993, and since then, it has become 
the favorite form of ablation for small tumors. When 
comparing RFA with PEI, the former showed to be 
better in relapse prevention and in improving tumor 
necrosis[30]. However, surgical resection is so far very 
superior to PA techniques.
Chemoembolization: TAE is another locoregional 
palliative treatment option in cases where surgical 
resection or other forms of treatment with curative 
potential are not advised for specific HCC tumors. The 
hepatic artery is responsible for the supply of blood 
to the tumor; therefore, the obstruction caused by 
TAE produces extended tumor necrosis as a result of 
ischemia, thus providing the rationale for its wide use in 
patients with HCC[34]. When this procedure is performed 
in combination with chemotherapeutic agents such as 
doxorubicin and cisplatin, usually mixed with lipiodol, it 
is termed TACE. The addition of chemotherapy aims to 
enhance the anti-tumoral action of ischemia. Usually, 
in TACE, anti-neoplasic drugs are mixed with lipiodol. 
By injecting the patient with a combination of anti-
tumoral agents with the radio-opaque contrast agent 
lipiodol into the hepatic artery, drug delivery to tumor 
cells is expected to increase. Likewise, the chances 
of systemic side-effects related to chemotherapy 
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distributed tightly into the tumor while preserving 
normal tissue in the liver from the effects of high doses 
of radiation[41]. 
Selective internal radiotherapy: Intrahepatic 
radiotherapy, better known as radioembolization or 
selective internal radiation therapy (SIRT), is a therapy 
based on the intrahepatic delivery of Yttrium-90 
(Y-90)-labeled microspheres into the arteries that 
supply blood to the tumor, where the microspheres 
come into contact with tumor cells which are hit by 
radiation emitted by the radioisotope[46].
The microspheres are an implantable medical device 
consisting of resin-based or glass-based biocompatible 
microspheres loaded with Y-90[47,48].
The process of release of the microspheres occurs 
by using a flexible catheter inserted into the femoral 
artery which is moved forward by the radiologist until 
the hepatic artery is reached[47,49]. 
SIRT demonstrated an 89% treatment response with 
resin microspheres and 78% with glass microspheres, 
respectively, in patients suffering from HCC[49]. The 
median overall survival ranged 16.4-18 mo[50,51].
SIRT is a minimally invasive technique and a well-
tolerated therapy. It is a new therapy for treating liver 
cancer and liver metastases originated from colorectal 
cancer. 
Finally, SIRT represents a new therapeutic option 
for patients with unresectable HCC. Clinical studies 
showed an increase in terms of survival when this 
technique is used in combination with chemotherapy. 
Noteworthy, SIRT tends to reduce the size of the 
tumor and allows some patients to become eligible for 
surgical resection[52].
SBRT: As a means to ablate primary or metastatic 
liver tumors, technical advances in tumor localization 
and motion management were achieved.
SBRT has become an optimistic approach for the 
treatment of liver cancer as a result of the complex 
character of liver tumor motion along with the priority 
of decreasing the volume irradiated to the minimum to 
reduce the probability of RILD.SBRT[45].
Focal, high dose SBRT delivers ablative doses in 
fewer fractions and highly conformational radiotherapy 
volumes[43].
To avoid damaging nearby critical structures and 
organs, doses are minimized using tight margins. A 
robust immobilization device is thus crucial to achieve a 
reproducible and accurate setup. Image guidance can 
be accomplished by using a megavoltage/kilovoltage 
cone beam computed tomography (CT) or stereoscopic 
X-rays[43]. The local tumor control of SBRT turns out to 
exceed that of conventional fraction EBRT[42].
A retrospective analysis carried out by Choi et al[53], 
demonstrated that a dose of 50 Gy of SBRT in 5 or 10 
fractions for primary liver tumor produced a median 
survival of 20 mo. Another study carried out by Tse et 
al[54] using SBRT at a dose of 24-54 Gy in 6 fractions, 
are expected to decrease. Unfortunately, the use of 
either TAE alone or TACE, remains a controversial 
treatment approach for patients with HCC, because 
some randomized controlled trials have failed to disclose 
a significant benefit in terms of survival of treated 
patients as compared with untreated patients[34,35]. 
Moreover, several studies demonstrated disappointing 
results, showing that TACE enhances intrahepatic and 
extrahepatic metastases, and even reduce survival[36]. 
Accordingly, anti-angiogenic therapy enhances the 
efficacy of transcatheter arterial embolization for HCC 
hepatocellular carcinomas[37]. 
Furthermore, severe side-effects produced by the 
arterial obstruction and by the toxicity of the injected 
anti-tumoral agents during the TACE procedure, 
counteract the anti-tumoral action resulting from 
arterial obstruction. It should be highlighted that the 
absence of effects due to chemotherapy is not the 
result of ineffective drug delivery but of the presence of 
MDR due to the over-expression of efflux pumps that 
belongs to the ABC superfamily of protein transporters, 
as well as to an abnormal p53 function that leads to an 
inhibition of apoptosis making tumor cells resistant to 
anti-tumoral treatment[38-40]. Dysfunctional p53 makes 
tumoral cells also less sensitive to hypoxia.
Radiation therapy
External beam radiation therapy: Before the 
1990s, external beam radiation therapy (EBRT) has 
played a minor role in the primary treatment of HCC. 
However, EBRT was mainly used in the palliative setting 
for metastatic disease because of an intolerance of 
the adjacent normal liver to tolerate radiation that 
precluded a more intense use of radiation[41]. 
In 1987, the radiation therapy oncology group 
outlined the outcomes of a randomized clinical trial 
including radiotherapy of the whole-liver with a dose 
of 21 Gy in seven fractions or combined with the 
radiosensitizer misonidazole[42]. Although a whole-
liver EBRT provided a significant palliative effect, the 
addition of misonidazole did not significantly improve 
the outcomes[43]. 
The dose-limiting complication of delivering EBRT 
to the liver is radiation-induced liver disease (RILD) a 
clinical entity characterized by the presence of anicteric 
hepatomegaly and ascites (associated with high 
levels in sera of hepatic enzymes) that may lead to 
liver failure and death[44]. Due to this reason, several 
approaches were designed by researchers at the 
University of Michigan to administer higher radiation 
doses to smaller liver portions, in order to produce 
greater tumor control rates without an increase in the 
damage to the liver parenchyma that is likely to be 
caused by radiation[45].
Based on the above, with the advent of intensity-
modulated radiation therapy, image-guided radiation 
therapy and stereotactic body radiation therapy (SBRT; 
as described below, separately), higher doses could 
be delivered safely since the radiation dose can be 
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demonstrated that the median survival rate turned out 
to be 13.4 mo.
Although liver metastasis is not the subject of the 
present review, it is noteworthy to point out that survival 
outcomes are better in patients with liver metastasis 
than with HCC. In both groups, there appears to be 
a dose-response for local control. For HCC, the dose 
of SBRT should be based on the cirrhotic status. For 
patients with Child-Pugh A cirrhosis, 48 Gy or higher 
distributed in 3 fractions is recommended. For patients 
with Child-Pugh B cirrhosis, more fractionated schemes 
are suggested (5 fractions of 40 Gy, for example). For 
liver metastases, doses greater than 48 Gy divided into 3 
fractions or 14-26 Gy in one fraction is recommended[43].
Finally, with the use of innovative tools combined 
with radiotherapy such as advanced imaging and 
immunotherapy, further advances in liver cancer could 
be achieved. Research is under way to analyze the way 
of optimizing radiation delivery by using other procedures 
such as TACE and sorafenib administration[45]. 
Systemic treatments
Hormonal therapy: Since 15%-39% of HCC express 
estrogen receptor (ER), and overexpression of the 
progesterone receptors was detected in up to 39% of 
tumors, in the last decades there have been clinical trials 
with tamoxifen for patients with HCC[55,56]. However, later 
studies have shown that patients suffering from HCC 
and receiving tamoxifen did not have a survival benefit, 
reaching the conclusion that this anti-estrogen drug, 
either alone or in combination with other chemotherapy 
agents to treat advanced HCC is ineffective. According 
to Di Maio et al[57], a possible explanation for these 
unfavorable results resides on the selection of the 
patients in the clinical trials, since none of them had 
selected patients based on the expression-status of 
the hormonal receptor. Therefore, this constitutes a 
significant problem. It should be pointed out that in 
breast cancer, for example, it is well known that the 
adequacy of hormonal treatment is pertinent; however, 
it is only restricted to those patients having tumors 
with expressed hormone receptors. Moreover, in some 
HCC patients, a variant form of the ER alpha (vER) 
transcript derived from an exon 5-deleted transcript 
lacking the hormone-binding domain of the receptor, 
yet having an intact DNA-binding domain keeps 
constitutive transcriptional activity. These tumors with 
vER, which account for an important percentage of 
HCCs, have a bleaker prognosis characterized by faster 
doubling time and shorter survival[57]. Tamoxifen is 
ineffective in the treatment of tumors with vER because 
tamoxifen is not able to bind to the receptor. Thus, 
by choosing anti-hormonal treatment according to 
the presence of wild-type or variant ERs in the tumor, 
a significant improvement to the response rate to 
tamoxifen is observed[58]. Efficacy of megestrol acetate 
has been tested in HCC tumors expressing vER in a 
randomized study of 45 patients with advanced HCC. 
Although in this study it was observed that megestrol 
notoriously increases survival in this reduced group of 
patients (untreated patients: 7 mo; patients treated 
with megestrol: 18 mo)[59], an adequately powered 
randomized trial should be carried out to confirm these 
results. 
As in the case of estrogens, it has been proved 
that androgens positively influence HCC growth; thus, 
androgens or luteinizing hormone-releasing hormone 
agonists (nilutamide, goserelin acetate, triptorelin, 
flutamide, leuprorelin) will possibly play a part in 
treating HCC. However, no benefit in terms of survival 
was found with anti-androgenic treatment in male 
patients with advanced HCC[60,61].
Finally, hormonal compounds have proved to be 
totally ineffective as regards patient survival. Although 
tamoxifen and anti-androgen drugs failed to prolong 
survival in advanced HCC cases, somatostatin -whose 
receptor is expressed in HCC - and its synthetic analogs 
like octreotide may play a role in prolonging survival in 
patients with advanced disease[57]. However, the results 
obtained so far are conflicting; therefore - as in the 
case of megestrol- further studies are required.
Systemic chemotherapy: Many patients seek 
systemic chemotherapy and for more than 50 years, 
conventional systemic cancer chemotherapy has been 
developed with the so-called anti-tumoral agents. 
However, in patients with HCC, the role of chemotherapy 
is quite limited due to inefficacy and toxicity of these 
antineoplastic drugs[62]. Single chemotherapy with 
cytotoxic agents such as cisplatin or 5-fluorouracil 
showed a low response rate (< 10%) without a clear 
benefit in overall survival[63]. In a recent clinical trial 
involving a large number of HCC patients, systemic 
administration of doxorubicin has provided a very low 
response rate (4%)[64].
Combination therapy is broadly regarded as a 
treatment option and used in oncology practice to 
enhance the efficacy of systemic chemotherapy. Moreover, 
it is the only treatment choice for those patients in 
whom unresectable HCC is not feasible for intra-arterial 
treatment. Although many regimens have not proved 
to be efficient for HCC patients, the combination of 
doxorubicin with paclitaxel (a microtubule stabilizer 
deemed to be one of the leading anti-tumoral agents 
in the past 10 years) showed a synergistic anti-tumor 
activity in vitro and in vivo[65].
A randomized phase Ⅲ trial assessing doxorubicin 
combination chemotherapy (cisplatin, interferon, 
doxorubicin and 5-fluorouracil, PIAF) revealed a higher 
overall response rate and better survival rates than 
those of patients receiving doxorubicin; unfortunately, 
these differences were not statistically significant. 
Moreover, increased toxicity was also related to PIAF[66]. 
The result in a double-blind phase Ⅱ multinational 
study assessing the treatment using sorafenib plus 
doxorubicin was greater median time to progression, 
overall survival and progression-free survival than 
doxorubicin monotherapy with treatment using sora-
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fenib[67]. However, the combination therapy of sorafenib 
and doxorubicin is not yet indicated for routine clinical 
use.
The poor response nature of HCC to systemic 
chemotherapy is mainly due to its extreme chemo-
resistance. Overexpression of several members 
belonging to the ABC-transporters superfamily leads 
to its MDR phenotype. At present, there is an intense 
search of agents for overcoming MDR, as it is discussed 
in the last section. 
Immunotherapy: Immunotherapy is considered to 
be a possible treatment choice for those suffering from 
HCC, mainly as a second-line treatment to prevent 
relapse. In accordance with previous studies, there 
is direct correlation between patient survival and the 
the type and number of immune cells infiltrating the 
tumor, which indicates that there is a direct effect of 
immune responses on the disease evolution[68]. 
Immunotherapy represents an attractive alternative 
tool based on sensitivity, specificity against tumor 
cells, on the immune system capacity to renew itself, 
and its potential to eradicate residual tumors after 
conventional treatment. Therefore, results from several 
clinical trials have shown that immune-based therapy 
can improve outcomes in patients with HCC[69].
A randomized clinical trial demonstrated that there 
were statistically significant improvements in relapse 
time and relapse-free survival with the administration 
of interleukin 2 (IL-2) and anti-CD3 activated peripheral 
blood mononuclear cell in HCC patients that underwent 
surgical resectionl[70].
Interferons (IFNs) have immunomodulatory and 
anti-proliferative activities on tumor cells, and are widely 
used as therapy for neoplasias and viral diseases[71]. 
A randomized study carried out by Lai et al[63], reported 
that recombinant IFN-α turned out to be superior to 
doxorubicin in terms of survival, tumor response and 
toxicity in patients with unresectable HCC, both in 
prolonging survival and in inducing tumor regression.
One area of active research is immunotherapy with 
cytokine-induced killer cells (CIK)[71]; unfortunately, 
its efficiency is limited because of its low specificity to 
cancer cells. Another approach is the tumor-associated 
antigen (TAA)-pulsed dendritic cells (DC) therapy, but 
the outcomes remain unsatisfactory due to the poor 
immunogenicity of TAA that make tumor cells to fail 
to adequately stimulate DCs for effective presentation 
to immune cells[72]. A possible method for increasing 
the uptake of TAAs by DCs is to complex them with an 
IgG antibody, so that the resulting immune complexes 
may bind to Fcγ receptors (Fcγ-Rs) on DCs and induce 
phagocytosis of TAAs, leading to an effective immune 
response against the tumor cells[73]. Such targeting 
strategy was achieved by complexing the tumor 
cell membranes expressing α-Gal epitopes (Gal-α1, 
3Gal-β1, 4-GlcNAc-R, α-Gal) with the anti-Gal IgG 
antibody (a natural antibody comprising 1% of IgG in 
humans)[74]. This opsonized binding complex may be 
phagocyted by DC and then enhance TAA presentation 
to naïve T or CIK cells, which are then activated and 
attack the remaining tumor cells in vivo[75]. In this 
study, the authors demonstrated that this anti-tumor 
vaccine could significantly increase the tumor-specific 
immune responders in circulation and the survival of 
advanced HCC patients (17.1 mo vs 10.1 mo in control 
groups) with no serious side effects. 
In addition, results from a larger trial testing 
infusion of antigen-presenting cells that included 31 
HCC patients receiving autologous tumor lysate-pulsed 
DC, showed an important 1 year survival (63% vs 
10%), which supports the idea of immunotherapy for 
HCC based on DC[76].
Inmunotherapy was also supported by rat models, 
since it was shown that there was a reduction in HCC 
relapse when administering DC in combination with 
IL-12 activated T and NK cells[77].
Antigen-specific immunotherapy and Treg (CD25+ 
T-cells) depletion are worth mentioning as promising 
plans of action in physiologically important HCC 
preclinical models[68]. For example, immunization with 
a DNA-based synthetic vector (DNAmAFP/704) as an 
antigen-specific approach for targeting α-fetoprotein 
(AFP) proved to considerable reduce (65%) the tumor 
burden in an autochthonous model of a chemically 
produced hepatocarcinoma. Similarly, CD25+ T-cell 
depletion by injecting the PC61 antibody significantly 
protected against tumor growth in an orthotopic HCC 
model[68]. Treg-depleting reagent Denileukin difitox 
(Ontak) targets the constitutively expressed molecule 
CD25, thus producing the elimination of circulating 
Tregs without coordinating depletion of activated 
CD25-expressing T effector cells[78].
Another research work reported that the ex vivo 
treatment of CD8+ T cells isolated from HCC patients 
with CTLA-4 blocking antibodies (ipilimumab) produced 
an expanded antigen-specific T cell repertoire, 
suggesting that this monoclonal antibody is likely to be 
highly effective in the treatment of HCC[79].
Direct reactivation of hyporesponsive tumor-specific 
T cells by providing T cell growth factors (IL-15, IL-7) 
or costimulatory agonists (anti-4-1BB, anti-OX40)[80,81] 
is another possible approach to successfully deal with 
tumor-mediated immunosuppression.
Furthermore, the use of therapeutic reagents 
inducing chemokine and adhesion molecule expression 
through blood vessel activation is also an interesting 
strategy for HCC treated with immunotherapy, since 
this kind of strategy may help restore T cell infiltration 
of the tumor[82].
Finally, it is expected that chemoimmunotherapy, 
that is, immunotherapy in combination with conventional 
therapy or other types of immunotherapies will elicit 
synergistic anti-tumor activity.
It has been earlier suggested that during or 
immediately following ablative therapy, immunotherapy 
will have its highest observed efficacy when tumor cells 
are about to die and the immune response has begun 
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its activity. In HCC, combined therapy of TAE with intra-
tumoral DC infusion produced higher frequencies of 
AFP-specific T cells in comparison with TAE alone[83,84].
Advantageous therapeutic approaches in HCC will 
probably include combinations of immunotherapy 
involving several immune effector mechanisms, such 
as vaccines and T cell immune-modulators, along 
with immunotherapy supplemented with molecularly 
targeted inhibitors of tumor signaling pathways[84].
MOLECULAR TARGETED THERAPY
In the last decades, research on the molecular 
pathology of HCC has uncovered a plethora of molecules 
that are critical in the onset and progression of this 
human disease. With regard to cancer investigation, 
in order to target key molecules involved in cancer 
genesis and growth, several compounds for disease 
treatment were developed. The present section 
summarizes the status of the different therapeutic 
compounds developed for the targeting members of 
different signaling pathways that are crucial in the 
pathogenesis of HCC, e.g., inhibitors of the epidermal 
growth factor receptors (EGFR) and the vascular EGFR 
(VEGFR), families, as well as inhibitors of the TGF-β 
and the mTOR signaling pathways (Table 1 and Figure 
1). 
Anti-angiogenic therapy
HCC is one of the most vascularized solid tumors, having 
high vascular endothelial growth factors (VEGF) and 
microvessel density levels. In addition, other relevant 
angiogenic factors involved in HCC pathogenesis are: 
VEGFs, fibroblast growth factors (FGFs) and platelet-
derived growth factors (PDGFs). 
VEGF seems to be primary a mediator of angiogenesis 
in HCC. Moreover, a higher level of VEGF is associated 
with a more aggressive disease evolution and possible 
poor treatment response[85]. Therefore, VEGF/VEGFRs 
and PDGF/PDGFRs signaling pathways are prime targets 
for the development of anti-angiogenic treatments for 
cancer. The anti-VEGF antibody bevacizumab and the 
multi-targeted tyrosine kinase inhibitors (TKI) sunitinib, 
sorafenib and pazopanib, which inhibit VEGFRs and other 
receptor tyrosine kinases are agents approved by the 
FDA to directly aim at the VEGF pathway[86]. So far, the 
only agent that has been proven to be effective in terms 
of survival of patients with HCC is sorafenib, which has 
become the current standard for palliative treatment[86]. 
Unfortunately, resistance to anti-angiogenic therapy 
was described (Figure 2). Hypoxia-Inducible Factor-1α 
and -2α (HIF-1α and HIF-2α) may be caused by the use 
of anti-angiogenic agents due to constriction of tumor 
blood vessels, decrease in blood flow and intratumoral 
hypoxia[87]. HIF-1α and HIF-2α transactivate genes 
causing tumor angiogenesis, tumor cell growth and 
energy metabolism, therefore causing anti-angiogenic 
drugs to become resistant and leading to poor 
prognosis[88]. It was reported that HCC overexpress HIF-
1α and that this overexpression is triggered by tissue 
hypoxia, aberrant growth factor receptor signaling and 
mutations in oncogenes and tumor supressor genes[87]. 
Furthermore, previous cancer experiences have 
shown that the expression of other angiogenic factors 
such as the FGF are up-regulated upon anti-VEGF 
treatment as an alternate escape mechanism. Thus, 
inhibitors of the FGF pathway such as brivanib were 
recently investigated for the treatment of advanced 
HCC as an option for patients with HCC following failure 
of sorafenib. 
Sorafenib: Sorafenib is a multitargeting small 
molecule that exerts its anti-angiogenic effect through 
inhibition of VEGFR-1, VEGFR-2, VEGFR-3, CD135 
or Fms-like tyrosine kinase-3 (Flt-3), PDGFR-β, and 
FGF receptor-1 (FGFR-1) promoting the formation 
of new blood vessels[89]. Sorafenib also acts blocking 
cellular proliferation mediated by the Raf/MAPK/ERK 
signaling pathway[89] and inducing both apoptosis and 
autophagy in human hepatoma cells[90,91]. As previously 
mentioned, the FDA has approved sorafenib for treating 
both HCC and renal cell cancer in 2007, and is the first 
systemic therapy to show some survival advantage. In 
2008, a promising prospect for sorafenib monotherapy 
in the treatment of advanced HCC had been provided 
by a multicenter double-blind Phase Ⅲ trial (the 
Sorafenib HCC Assessment Randomized Protocol) which 
demonstrated a 44% increase in the median overall 
survival (10.7 mo in the sorafenib group and 7.9 mo 
in the placebo group)[24]. In the following year, an Asia-
Pacific trial corroborated sorafenib efficacy reporting 
a median overall survival of 6.5 mo, whereas in the 
placebo group the reported median overall survival was 
4.2 mo[92]. However, problems of drug-toxicity have 
been reported; among the most frequently observed 
drug-related adverse events, fatigue, anorexia, 
diarrhea, rash/desquamation, and hand - foot skin 
reactions were described[93]. Furthermore, other studies 
have shown that patients with severe liver dysfunction 
had a limited life expectancy after treatment with 
sorafenib (1.5 mo)[94]. In a meta-analysis of five 
randomized controlled trials encompassing 1462 
patients with unresectable HCC, Shen et al[95], have 
recently shown that sorafenib use - as compared with 
placebo - improved the disease control rate (RR = 
1.85, 95%CI: 1.55-2.20, P < 0.001), decreased tumor 
progression (HR = 0.61, 95%CI: 0,51-073, P < 0.001) 
and reduced mortality (HR = 0.71, 95%CI: 0.56-0.89, 
P < 0.001). Interestingly, further subgroup analyses 
demonstrated that results obtained were not modified 
by HCC etiology, performance status nor Barcelona 
Clinic Liver Cancer-stage[95] (Figure 3). Sorafenib has 
also shown benefit when combined with doxorubicin. 
In a phase I study combining sorafenib/doxorubicin, all 
four patients with metastatic HCC maintained stable 
disease state for more than 1 year of treatment[96]. In a 
randomized, double-blind, phase Ⅱ trial, the sorafenib/
doxorubicin combination prolonged the median overall 
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survival and progression-free survival when compared 
with doxorubicin alone[97].
A phase Ⅱ multicenter study of combined sorafenib/
octreotide showed a higher disease control rate than 
sorafenib monotherapy (76% vs 43%, respectively) 
achieving an overall survival of 12 mo[98] sorafenib combined 
with TACE is currently under clinical investigation[99]. 
Inhibition of autophagy with specific pharmacological 
inhibitors such as chloroquine, produced more pronounced 
tumor suppression in HCC in vivo and in vitro[24]. Thus, 
the combination of sorafenib and autophagy modulation 
is a promising therapeutic option in unresectable HCC[91]. 
Moreover, up-regulation of HIF-2α induced by sorafenib 
contributes to drug resistance by activating the TGF-α/
EGFR pathway in HCC cells[100], overcoming the negative 
modulation exerted by HIF-1α (Figure 2). 
Bevacizumab: The FDA also approved a recombinant 
monoclonal anti-VEGF antibody to be used in advanced 
breast, non-squamous non-small cell lung and colorectal 
cancers in combination with chemotherapy. In Siegel’
s Phase Ⅱ study it was shown that bevacizumab as 
a single agent was effective, showing a 13% rate of 
objective tumor response and a median overall survival 
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Table 1  Molecular targeted therapy
Type of drug Drug Target Stage of use (for HCC)
Inhibitors of angiogenesis Sorafenib1 VEGFR members Approved
PDGFR-β
Flt-3
FGFR-1
Raf/MAPK/ERK signaling pathway
Bevacizumab VEGFR members Phase Ⅱ
Sunitinib VEGFR members Phase Ⅱ
PDGFR-α
PDGFR-β
Flt-3
c-Kit
RET kinases
Pazopanib VEGFR members Phase Ⅰ
PDGFR-α
PDGFR-β
c-Kit
Brivanib VEGF signaling pathway Phase Ⅱ
FGF signaling pathway
Axitinib VEGFR members Phase Ⅱ/Ⅲ
PDGFR-α
PDGFR-β
c-Kit
Linifanib VEGF Phase Ⅱ
PDGFR-α
PDGFR-β
TSU-68 VEGFR-2 Phase Ⅱ
PDGFR-α
PDGFR-β
FGFR-1
c-Kit
Flk-1
Foretinib VEGFR-2 Phase Ⅰ/Ⅱ
c-Met
Dovitinib VEGFR members Phase Ⅰ/Ⅱ
PDGFR-β
FGFR members
Flt-3
c-Kit
Ramucirumab VEGFR-2 Phase Ⅱ
Inhibitors of EGFR Erlotinib EGFR/HER-1 Phase Ⅱ
Lapatinib EGFR/HER-1 Phase Ⅱ
HER-2/NEU
Gefitinb EGFR/HER-1 Phase Ⅰ
Cetuximab EGFR/HER-1 Phase Ⅱ
Inhibitors of the mTOR pathway Rapamycin PI3K/Akt/mTOR pathway Phase Ⅰ/Ⅱ
Everolimus PI3K/Akt/mTOR pathway Phase Ⅰ/Ⅱ
1Sorafenib also induces apoptosis and autophagy. HCC: Hepatocellular carcinoma; VEGFR: Vascular endothelial growth factor 
receptors; Flt-3: Fms-like tyrosine kinase-3; FGFR-1: FGF receptor-1; MAPK: Ras-Raf-mitogen-activated protein kinase; EGFR: 
Epidermal growth factor receptors; FGF: Fibroblast growth factor; PDGFR: Platelet-derived growth factor receptors; RET: 
Rearranged during transfection; HER-1: Human epidermal growth factor receptor-1; mTOR: Mammalian target of rapamycin.
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of 12.4 mo in patients suffering from non-metastatized 
HCC unable to be resected[101]. However, its use was 
associated with considerable bleeding in 11% of cases 
and thrombosis in 6% of the patients, therefore it is 
prone to drug-related complications. Patients receiving 
the combination of bevacizumab with gemcitabine-
oxaliplatin (GEMOX)[102] or capecitabine-oxaliplatin[103] 
responded in up to 20% of cases, however the overall 
survival rate was 9.6 mo. The administration of these 
drugs also resulted in considerable toxicity associated 
with the treatment, causing leukopenia, transaminitis, 
hypertension and fatigue. To summarize, it has been 
proved in previous clinical studies that bevacizumab 
was relatively effective in HCC; therefore, since some 
severe drug-related complications such as thrombosis, 
hemorrhage and even death have been reported, 
further studies are needed to clarify its efficacy and 
safety.
Sunitinib: Sunitinib is an oral multi-targeted TKI 
that inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, 
PDGFR-β, c-kit, Flt3, and rearranged during transfection 
(RET) kinases. Sunitinib has been approved by the 
FDA to treat renal adenocarcinoma and gastrointestinal 
stromal tumors. In a phase Ⅱ clinical trial to analize 
the efficacy of sunitinib as monotherapeutic agent in 
advanced stages of HCC, it was reported that this drug 
shows modest antitumor activity with a very low rate 
response and a median overall survival between 8 and 
9.8 mo[104]. It is worth mentioning that sunitinib had 
been negative for its primary overall survival endpoint 
and proved to have greater toxicity than sorafenib. Thus, 
based on these results, the use of sunitinib as first line 
treatment in advanced HCC was not supported, being 
sorafenib monotherapy the standard of care in these 
cases. However, when sorafenib fails, sunitinib might be 
chosen as second-line treatment[105]. 
Pazopanib: Pazopanib, a synthetic indazolyl-pyrimidine 
is an oral angiogenesis inhibitor, recently approved 
by FDA for the treatment of patients with renal cell 
cancer[106]. This novel multitargeted TKI acts inhibiting 
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β and 
c-Kit. It is still being assessed as potential treatment for 
HCC[107]. Phase Ⅰ clinical studies established that since 
the toxicity level of pazopanib is acceptable, it might be 
a possible option for advanced HCC treatment[108]. 
Brivanib: Brivanib, a TKI, is the first oral selective dual 
inhibitor of VEGF and FGF signaling pathways, that has 
showed encouraging antitumor activity in preclinical 
and phase Ⅰ studies. In a phase Ⅱ open-label study 
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of brivanib as first-line therapy in patients with 
unresectable, locally advanced, or metastatic HCC, 
brivanib demonstrated promising antitumor activity 
with a median overall survival of 10 mo. Furthermore, 
this anti-angiogenic drug showed a manageable safety 
profile, being fatigue, diarrhea, anorexia, vomiting, 
hypertension, constipation and nausea the most 
frequent reported adverse events[109]. In another 
phase Ⅱ, open label study of brivanib, which this time 
was assessed as a second-line drug treatment for HCC 
patients not responding to the administration of anti-
angiogenic therapy, showed encouraging results in this 
group of patients for whom no approved treatment 
is currently available[110]. Recently, a multinational, 
randomized, double-blind, phase Ⅲ trial compared 
brivanib with sorafenib as first-line treatment for HCC. 
Results demonstrated that both drugs displayed a 
similar anti-tumor activity, based on secondary efficacy 
end points, although brivanib was less well-tolerated 
than sorafenib[111]. Finally, brivanib, as an adjuvant 
therapy to TACE in patients with HCC, failed to improve 
overall survival[112].  
 
Axitinib: Axitinib is another multi-targeted TKI with 
activity against VEGFR-1, VEGFR-2, VEGFR-3, VEGFR-4, 
PDGFR and c-Kit. This drug has shown promising results 
for renal cell cancer and thyroid cancer. Phase Ⅱ/Ⅲ 
trials assessing this medication for HCC are still being 
planned[113,114].
Linifanib: Linifanib is an innovative and potent selective 
inhibitor aimed at inhibiting angiogenesis, tumor growth 
and metastasis. A phase Ⅱ clinical trial in patients 
undergoing the advanced stages of HCC showed that 
linifanib is clinically active for unresectable HCC with 
an acceptable safety profile. The median overall survival 
was 9.7 mo. A phase Ⅲ trial for comparing linifanib with 
sorafenib is currently under way[115].
TSU-68: TSU-68 is an oral compound which inhibits 
VEGFR, PDGFR and FGFR. A phase Ⅰ/Ⅱ clinical trial 
in patients with advanced HCC has shown promising 
efficacy with a median overall survival of 13.1 mo and 
a high safety profile even in patients who had been 
heavily pre-treated[116]. 
Foretinib: Foretinib is a novel receptor TKI that targets 
VEGFR-2 and c-Met that demonstrated significant 
anti-tumor activities in preclinical models of HCC. At 
present, phase Ⅰ and Ⅱ clinical trials are under way[117].
Dovitinib
Dovitinib potently inhibits receptor TKs, showing 
specificity for VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, 
FGFR-1, FGFR-2, FGFR-3, Flt-3 and c-Kit. Several 
phase Ⅰ/Ⅱ studies have been carried out to assess 
the efficacy, pharmacokinetics, pharmacodynamics 
and safety profile of this drug. In xenografts models 
of human HCC it was reported that this compound 
reduced angiogenesis and cell proliferation, inducing 
apoptosis of tumor cells[118].
Ramucirumab: Ramucirumab is a recombinant human 
monoclonal antibody that binds to the extracellular 
domain of VEGFR-2. A phase Ⅱ study of ramucirumab 
as first-line monotherapy in patients with advanced 
HCC showed that this monoclonal antibody has been 
well tolerated and has conferred a moderate disease 
control[119].
Inhibitors of the human EGFR 
It has been broadly accepted that the role of growth 
factors and their receptors is crucial for several cancers 
to develop and progress, HCC among them[120]. In 
fact, inhibitors of the human EGFR-1 (HER-1) is usually 
overexpressed in chronic hepatitis, fibrosis, cirrhosis and 
HCC cases[121]. EGFR/HER-1 ligands such as epidermal 
growth factor (EGF), hepatocyte growth factor, TGF-α, 
TGF-β, and insulin-like growth factors (IGF) were shown 
to be mitogenic for hepatocytes, therefore contributing 
significantly to hepatocarcinogenesis[122]. Furthermore, 
hypomethylation of the EGFR/HER-1 gene was also 
described to be associated with the development of 
HCC[123]. Since drugs targeting EGFR have proved to 
increase survival rates in patients in whom cancer has 
metastized to the lungs and pancreas[124,125], there 
is a logic for analyzing the effectiveness of this novel 
class of compounds in patients with unresectable HCC. 
Regarding HER-2/NEU and its significance in HCC, the 
international literature shows conflicting data. Some 
studies have demonstrated that HER-2/NEU is rarely 
overexpressed in HCC and might not play a role in 
this kind of cancer[126], whereas the opposite has been 
shown by other studies[127].
Erlotinib: Erlotinib is an orally active selective inhibitor 
of the EGFR/HER-1-related thymidine kinase (TK) 
enzyme that inhibits its autophosphorylation process[128]. 
Erlotinib blocks the EGF-dependent growth of tumoral 
cells at submicromolar concentrations and arrests 
cell-cycle progression in the G1 phase[129]. FDA has 
approved this selective inhibitor of the EGFR/HER-1-
related TK enzyme for treating advanced lung and 
pancreatic cancers. A phase Ⅱ study of the single-agent 
erlotinib in patients with unresectable HCC reported 
that tolerance to this drug was good but had a modest 
benefit in controlling HCC, which was evidenced as a 
13-mo discrete prolonged overall survival[130]. However, 
another phase Ⅱ study demonstrated a median 
overall survival of 10.75 mo[129]. Interestingly, it was 
also demonstrated in this study that overall survival 
between the group of patients that showed high EGFR/
HER-1 expression and those with low EGFR/HER-1 
expression was not significantly different[129]. This 
means that there was no correlation with EGFR/HER-1 
expression and overall survival. The toxicity to erlotinib 
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was mainly cutaneous and similar in profile to other 
drugs that target the EGFR/HER-1-related TK activity. 
A phase Ⅱ, single-arm, open-label trial of erlotinib in 
combination with bevacizumab obtained encouraging 
results and a favorable toxicity profile. The best 
response showed minor tumor shrinkage, decreased 
tumor vascularity or increased necrosis. Adverse effects 
consisted on transaminases elevation, hyperkalemia, 
diarrhea, proteinuria, gastrointestinal bleed, fatigue 
and hypertension[130]. Further studies with erlotinib as 
a single agent or in combination with other agents are 
needed. 
Lapatinib: Lapatinib is a dual inhibitor of EGFR/
HER-1 and HER-2/NEU by docking into the ATP-
binding site of the two receptors, thus inhibiting their 
autophosphorylation and the corresponding downstream 
signaling with consequent down-regulation of MAPK, 
AKT and p70S6 kinase, inhibiting tumor growth[131]. 
Clinical studies using lapatinib demonstrated that this 
drug was well-tolerated and displayed anti-tumor 
activity in heavily pretreated patients with several solid 
tumors. The most common adverse effects reported 
were rash and diarrhea. Lapatinib was recently approved 
by the FDA for use in metastatic breast cancer[132]. A 
phase II study of single agent lapatinib in patients with 
advanced HCC demonstrated that this drug was well-
tolerated but revealed a minimal anti-tumoral activity 
based on the lack of objective responses and an overall 
survival of 12.6 mo[133]. The use of single-agent lapatinib 
in advanced HCC was tested in another phase Ⅱ study 
which revealed a lower median overall survival of 6.2 
mo. Authors reported that this low median survival 
might be due to the small sample size. Anyway, they 
concluded that treatment with lapatinib failed to 
meet predefined efficacy standards and did not have 
significant activity on HCC[134].
Gefitinib: Gefitinib, an adenosine triphosphate 
mimetic anilinoquinazoline is an orally active EGFR-
TKI that reduces EGF-stimulated tumor cell growth[135]. 
Results from the Eastern Cooperative Oncology Group’
s Study E1203 had shown modest activity in advanced 
HCC with a median overall survival of 6.5 mo[136]. 
Interestingly, combination of gefitinib and sorafenib 
has demonstrated synergistic effects to inhibit cell 
proliferation by promoting apoptosis in vitro and tumor 
growth suppression in vivo[99].
Cetuximab: Cetuximab is a chimeric (human and 
mouse) monoclonal antibody directed against EGFR, 
approved by the FDA for the treatment of squamous 
cell carcinoma of the head and neck and metastatic 
colorectal cancer. In phase Ⅱ clinical studies in 
patients with advanced and unresectable HCC, the 
use of cetuximab - as single agent therapy, as well as 
in combination therapy with GEMOX - demonstrated 
modest activity[137,138].
Inhibitors of the mTOR pathway
The PI3K/Akt/mTOR signal pathway is crucial in 
promoting protein synthesis and is implicated in various 
cellular functions such as proliferation, differentiation, 
tumorigenesis and apoptosis. In approximately 
15%-41% of HCC patients, activation of this signaling 
pathway has been reported[139]. This event is implicated 
in metastasis, invasion and poor prognosis[140]. Blocking 
the mTOR pathway confers anti-cancer, anti-angiogenic 
and immunosuppressive properties. Preclinical data 
have shown that mTOR inhibitors were effective in both 
cell growth and tumor vascularity suppression in HCC 
cell lines and HCC tumor models[141]. According to this, 
rapamycin -the naturally occurring inhibitor of mTOR 
- and a number of recently developed rapamycin-
analogues inhibit the growth of cell lines derived from 
multiple tumor types in vitro and tumor models in vivo. 
LY294002 is a PI3-kinase inhibitor that decreased the 
viability of HCC cells by inhibition of Akt activation. 
Other Akt inhibitors include wortmannin and inhibitor 
Ⅷ[142].
In addition, cyclooxygenase-2 (COX-2) has been 
recently implicated in the pathogenesis of HCC through 
Akt activation. According to this, the level of COX-2 
expression and Akt phosphorylation is positively 
correlated in cultured HCC cells and human liver cancer 
tissues[143]. In this regard, Leng et al[143] demonstrated 
that HCC cells treated with the COX-2 inhibitor celecoxib 
showed significant reduction of Akt phosphorylation and 
induced apoptosis.
Sirolimus: Sirolimus (Rapamycin) is a macrolide 
antibiotic and antifungal drug isolated from Streptomyces 
hygroscopicus. Since it has been proved to have both 
immunosuppressive and antiproliferative effects, it 
has been regarded as an adjuvant therapy designed 
to treat cancer[88]. This specific mTOR inhibitor exerts 
its action in association with its intracellular receptor 
FKBP-12. Sirolimus may both inhibit rejection in liver 
transplantation patients and prevent the recurrence of 
HCC[144]. 
Everolimus: Everolimus is an oral inhibitor of mTOR. 
A phase Ⅰ/Ⅱ study carried out in patients with 
unresectable or metastatic HCC showed modest anti-
tumor activity with a median overall survival of 8.4 
mo and a disease control rate of 44%. Everolimus 
was well tolerated in patients with advanced HCC. 
The most frequent adverse effects reported were 
fatigue, hyperglycemia, diarrhea, anemia, leukopenia 
and lymphopenia, thrombocytopenia, hyponatremia, 
anorexia, stomatitis and rash[145]. 
Curcumin
Curcumin is a naturally occurring and biologically active 
compound extracted from the rhizomes of Curcuma 
longa. In vitro, it was shown that this natural compound 
was able to induce apoptosis of HCC cell lines. In this 
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regard, Cao et al[146] reported that curcumin induced 
apoptosis in human HepG2 cells through mitochondrial 
hyperpolarization and damage.
Wang et al[147] also demonstrated that in HCC J5 
cells, curcumin induced apoptosis via Ca+2-regulated 
mitochondria-dependent pathway. 
Furthermore, curcumin has also been shown to 
inhibit several angiogenic biomarkers, including VEGF 
and COX-2 expression[148]. This means that curcumin 
could be used as a candidate for the combined drug 
therapy for HCC in the future.
Other drugs
Cediranib blocks VEGFR, PDGFR and c-KIT. Similarly, 
BIBF-1120 targets VEGFR, PDGFR and FGFR; E-7080 
inhibits VEGFR, FGFR, PDGFR and c-KIT; XL-184 
targets VEGFR-2, MET and RET; vandetanib targets 
VEGFR and EGFR; BIIB-022, AVE1642 and cixutumab 
inhibits IGF-1R; CT-011 inhibits PD-1/2; MEDI-575 
inhibits PDGFR; BAY73-4506 inhibits VEGFR, PDGFR, 
FGFR-1, Raf, RET, and c-KIT; GC33 inhibits Glypican-3, 
which is highly expressed in HCC; salirasib blocks ras 
and mTOR activation, and finally, PI-88, which targets 
heparanases as well as sulfatases is now in Phase Ⅲ 
clinical trials for the treatment of HCC[149].
DRUG DELIVERY SYSTEMS AND 
TARGETING STRATEGIES TO THE LIVER 
PARENCHYMA OF ANTI-TUMORAL 
COMPOUNDS
As described above, since HCC is asymptomatic at 
an early stage, most cases are often diagnosed when 
the disease has advanced and most of the potentially 
effective treatments such as surgical resection, 
orthotopic liver transplantation and local ablation 
demonstrate poor efficacy. In these advanced stages, 
systemic treatments are commonly used. However, 
the efficacy of the current anti-tumoral drugs used 
in advanced HCC treatment cause significant toxicity 
in other non-target organs, therefore influencing on 
the patients’ willingness to comply with and adhere 
to these treatments. Therefore, the effectiveness of 
treatments using anti-tumoral drugs for advanced 
HCC significantly depends on their pharmacokinetics, 
particularly in, their distribution and accumulation in 
the liver. An interesting approach to enhance anti-
HCC drug action is to direct them into the liver by drug 
delivery systems (DDS) that recognize hepatocyte 
surface receptors. Thus, those strategies targeting 
the drug to its site of action, - in this case, the liver - 
may cause an increase in drug efficacy and a decrease 
in possible collateral effects in other non-target 
organs[150]. Indeed, several studies discussed below, 
have attempted to target anti-tumoral drugs to the 
liver for the treatment of advanced HCC, using novel 
formulations including liposomes, polymeric micelles, 
polymeric nanoparticles, dendrimers, nanocapsules 
and microspheres. 
As mentioned above, since HCC originates from 
liver parenchyma cells, it is desirable to deliver drugs 
selectively to hepatocytes. To this end, asialoglycoprotein 
receptors (ASGPRs) are usually used as liver target due to 
their high expression on the surface of hepatocytes and 
in HCC-derived cell lines. ASGPRs specifically recognize 
ligands with terminal galactose or N-acetylgalactosamine 
residues, and endocytose them through an intracellular 
degradation process. The use of their natural ligand 
(asialofetuin) or synthetic ligands with galactosylated 
or lactosylated residues, has achieved significant 
targeting efficacy to the liver[22,151]. In this regard, Xu 
et al[152] synthesized a lactobionic acid conjugate of 
dioleoylphosphatidyl ethanolamine (Lac-DOPE) for 
targeting of solid lipid docetaxel-loaded nanoparticles. 
Following this approach, other works used the synthesis 
of lactosylated liposomes for targeted delivery of 
doxorubicin to HCC as a possible strategy to treat the 
disease[153]. Other groups used a cleavable poly(ethylene 
glycol) (PEG)-lipid [methoxypolyethyleneglycol 
2000-cholesteryl hemisuccinate, PEG (2000)-CHEMS] 
linked via an ester bond and a galactosylated lipid 
{(5-cholesten-3 beta-yl) 4-oxo-4-[2-(lactobionyl 
amido) ethylamido] butanoate, CHS-ED-LA} to modify 
doxorubicin. Results demonstrated that modification 
of liposomes with PEG (2000)-CHEMS and CHS-ED-LA 
turned out to be a potentially advantageous strategy for 
HCC therapy[154].
Polymeric micelles also constitute a safe and 
effective delivery system. Bei et al[155] designed three 
novel polymers named palmitoyl-trimethyl-chitosan 
(TPCS)-1, TPCS-2 and lac-TPCS-2, that hold a great 
potential in the development of nanomedicine for the 
therapy of liver tumors, especially lac-TPCS-2. On the 
other hand, polymeric micelles self-assembled from 
amphiphilic block copolymers of PEGs and poly(D,L-
lactide) (PDLLA) with folate as a targeting ligand 
attached to the distal ends of the PEG (Folate-PEG-
PDLLA) were prepared. Such Folate polymeric micelle 
was demonstrated to selectively deliver the anti-
tumoral drug doxorubicin to HCC cells, since they also 
overexpress surface receptors for folate[156]. Cuestas 
et al[157] reported the synthesis of galactosylated 
poly(ethylene oxide)-poly(propylene oxide) block 
copolymers, proposed for potential targeting to the 
liver.
The nanoparticle DDS, which uses polymeric 
material from natural or synthetic sources as a carrier 
in drug delivery to targeted tissues, has remarkable 
targeting, slow-release and biodegradable properties 
that also makes it a promising therapeutical option. 
Regarding this, Cheng et al[158] reported the use 
of chitosan and the hepatoma cell-specific binding 
molecule glycyrrhetinic acid to synthesize glycyrrhetinic 
acid-modified chitosan (GA-CTS). The anti-tumoral 
drug 5-fluorouracil (5-FU) was conjugated onto this 
newly synthesized nanomaterial, thus forming the 
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corresponding GA-CTS/5-FU nanoparticles. Results 
demonstrated that these nanoparticles accumulated 
selectively in the liver blocking tumor growth in an 
orthotopic liver cancer mouse model[158]. Another group 
reported the preparation of nanoparticles composed of 
galactosylated chitosan oligosaccharide and adenosine 
triphosphate for HCC cell-specific uptake[159].
Poly(amidoamine) dendrimers are branched water-
soluble polymers defined by consecutive generation 
numbers (Gn) indicating a parallel increase in size, 
molecular weight, and number of surface groups available 
for conjugation of bioactive agents. In this connection, 
Medina et al[160] targeted hepatic cancer cells with 
pegylated dendrimers displaying N-acetilgalactosamine 
and SP94 peptide ligands. Lactosylated dendrimers were 
also used as a liver-targeting DDS[161].
An alternative strategy is to use microspheres[162] 
and nanocapsules[163]. For example, Kang et al[163] 
reported an innovative hepatoma-targeted gene delivery 
system which was prepared with a combination of a 
human liver cell-specific bionanocapsule and a tumor 
cell-specific gene regulation polymer that responded to 
hyperactivated protein kinase C in liver cells. 
OVERCOMING MDR DUE TO 
OVEREXPRESSION OF ABC PROTEINS
As mentioned above, HCC is a molecular complex 
tumor with high intrinsic MDR (Figure 4). An increased 
cellular extrusion of chemotherapeutic drugs due to 
over-expression of MDR mediating ABC transmembrane 
proteins leads to a reduced effectiveness with response 
rates below 10%[164]. Actually, there are 49 known 
ABC transporters divided into 7 distinct subfamilies 
of proteins[165]. The most studied proteins were P-gp, 
MRP1 and BCRP.
A classic approach for overcoming MDR involves 
the use of low molecular mass ABC inhibitors co-
administered with the pharmacotherapeutic agent, such 
as verapamil and valspodar. However, limited success 
has been achieved so far with these chemosensitizing 
agents that inhibit these efflux proteins. New advances to 
overcome MDR consists on the use of block copolymers 
of poly(ethylene oxide) (PEO) and poly(propylene 
oxide) (PPO) also known as poloxamers or Pluronics
® and poloxamines or Tetronics® (Figure 5). Poloxamers 
consist of a central hydrophobic PPO molecule flanked 
on both sides by two hydrophilic chains of PEO. A 
slightly different structure is exhibited by poloxamines, 
which are tetrafunctional block co-polymers with four 
PEO-PPO blocks joined together by a central ethylene 
diamine bridge[166]. These surfactants have found a 
wide range of pharmaceutical, biomedical, clinical and 
nanotechnological applications. Some of them, such 
as Pluronic P85 were shown to sensitize MDR tumors 
refractory to many chemotherapeutic agents[167]. In 
addition, Cuestas et al[168] explored the prospective 
capacity of PEO-PPOs to overcome MDR in HCC-
derived cell lines. Results demonstrated that there is 
multiple-inhibitory activity of poloxamines on P-gp, 
MRP1 and BCRP in two human hepatoma cell lines, 
Huh7 and HepG2[168]. Copolymers of intermediate 
to high hydrophobicity (e.g., Tetronic® 304, 904 and 
1301) inhibited P-gp and BCRP but not MRP1 in both 
cell lines[168]. This activity was related to both copolymer 
concentration and hydrophobicity. Conversely, there was 
no evidence of an inhibitory effect in Tetronic® 1107, a 
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Figure 4  Mechanisms of multidrug resistance in cancer cells. (1) Active 
drug efflux by drug transporters, such as Pgp, multidrug resistance-associated 
protein, and breast cancer resistance protein; (2) Loss of cell surface receptors 
and/or drug transporters or alterations in membrane lipid composition; (3) 
Compartmentalization of the drug in cellular vesicles; (4) Altered/increased drug 
targets; (5) Alterations in cell cycle; (6) Increased drug metabolism/enzymatic 
inactivation; (7) Active damage repair; and (8) Inhibition of apoptosis. Reprinted 
with permission from ref. [181].
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Figure 5  Summary of Pluronic effects in cancer cells. Pluronic binding 
with plasma membrane of multidrug resistance (MDR) cancer cells (1) induces 
membrane fluidization, disruption of membrane microdomains, and inhibition 
of drug efflux transporters’ activity (Pgp shown as an example). Pluronic also 
reaches mitochondria where it (2, 3) inhibits complexes I and IV of mitochondria 
respiratory chain and (3) induces inner mitochondrial membrane depolarization. 
This (4) results in ATP depletion and (5) promotes cytochrome c release and 
ROS generation in MDR cells. Altogether, the MDR cells respond to a Dox/
Pluronic combination by (6) an increased proapoptotic signaling and decreased 
antiapoptotic defense. Reprinted with permission from ref. [181]. ROS: Reactive 
oxygen species.
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more hydrophilic counterpart[168]. Furthermore, the work 
by Cuestas et al[169], also analyzed for the first time the 
effect of branched PEO-PPOs on the expression of mRNA 
encoding for the main ABCs in a human hepatoma cell 
line and gave evidence of the down-regulation of mRNA 
levels corresponding to p-gp and bcrp[169].
All these technological strategies constitute a 
positive starting point that will require further research 
to evaluate their potential efficacy in treating HCC.
FUTURE PERSPECTIVES
HCC remains a disease with poor prognosis despite 
recent advances in the knowledge of both its 
pathophysiology and therapy. 
Since aberrant epigenetic deregulation events such 
as hyper-methylation (silencing) of tumor suppressor 
genes, hypo-methylation (activating) of proto-
oncogenes, as well as abnormal expression of histone 
modifying enzymes and non-coding RNAs (microRNAs 
and long non-coding RNAs) have been associated with 
genetic instability and altered gene expression, this 
landscape should be analyzed as a complex network 
of crosstalk and cooperation (synergism) leading 
to HCC. Bearing in mind the potential reversibility 
of epigenetic changes, plausible next generation 
treatments might also consider the use of drugs that 
modify DNA methylation and/or those that promote 
histone modifications (such as DNA methyl transferases 
- or histone deacetylases - inhibitors to activate tumor 
supressors), either as mono- or combined-treatment, 
together with conventional chemotherapeutic agents. 
Moreover, encouraging results obtained with the up-
regulation of some anti-tumoral miRNAs (such as 
adenoviral vectored-miR-122[170], and adeno-associated-
miRNA-26a[171], respectively) allow to consider this 
strategy as a candidate for the treatment of HCC[172]. 
Although only modest results have been thus far 
obtained with immunotherapy[173], a plausible use of 
immune-stimulating monoclonal antibodies (such as 
anti-CTLA-4/anti-programmed death ligand-1) together 
with inhibitors of the immune regulatory (suppressor) 
mechanisms exerted by Tregs and/or - as already 
demonstrated - locoregional conventional treatments 
intended to increase immunity and unmask TAA-specific T 
cell responses[174] might be envisaged as a next approach 
for HCC treatment. Moreover, the recent development 
of the calixarene compound OTX008[175] as an inhibitor 
of galectin 1[176] - a key regulator of extracellular matrix 
interactions, cell proliferation, invasion, angiogenesis 
and escape from the immune response by favoring the 
expansion of Tregs and the differentiation of tolerogenic 
dendritic cells, as well as by limiting T cell viability, and 
maintaining T cell anergy - promises a future view of 
tumor halting by selectively counteracting tumor immune 
escape[177]. A phase Ⅰ, first-in-man- study of OTX008 
treatment to patients with advanced solid tumors is 
ongoing (Clinical trial NCT01724320). Treating patients 
suffering from advanced HCC and overcoming MDR still 
remain an important challenge. Since an association 
between miR-122 down-regulation and MDR has been 
established, and an in vitro therapeutic effect on MDR of 
HCC cell lines with adenovirus-vector miR-122 has been 
reported[178], it seems plausible that miR-122 treatment 
in human HCC might be worth to evaluate. 
In this regard, a very recent report using cabozantinib 
(a VEGFR and MET inhibitor) demonstrated that patients 
with HCC with high level expression of phosphorilated-
MET (activated by the hepatocyte growth factor) 
are associated with resistance to adjuvant sorafenib 
treatment. The dual blockade of VEGFR2 and MET by 
cabozantinib leads to significant anti-tumor activities 
in HCC by suppressing both tumor growth and 
metastasis[179]. Therefore, the use of this drug might help 
to overcome to some extent the resistance to sorafenib. 
Likewise, the oral use of tivantinib in a Phase Ⅱ placebo-
control study demonstrated promising results in patients 
with HCC with high level of MET, which might be a 
second choice therapeutic in treating patients suffering 
from advanced HCC[180].  
The challenge of the heterogeneus nature of HCC 
- and the corresponding biomarkers - needs the 
expedited discovery of novel chemotherapeutic and 
immunotherapeutic agents, in order to have multiple 
choices for therapy which can then be used alone, in 
combination and/or sequentially, as wellas the design 
of technological or pharmaceutical strategies for 
chemosensitizing HCC cells. Furthermore, despite the 
availability of several drugs for the treatment of advanced 
HCC, implementing liver-targeting DDS strategies in 
general and nanotechnologies in particular may result in 
future tools to: (1) enhance the efficacy and application 
of approved drugs to overcome and delay cellular 
resistance development; (2) limit systemic side effects 
by promoting selective accumulation in the liver; and 
(3) increase patient adherence to treatment by reducing 
administration frequency. 
Finally, there are still many unknown technological 
drawbacks to be faced in the discovery and assessment 
of new drug candidates, which will demand the design 
of more suitable drug carriers to deal with their 
preliminary preclinical assessment. 
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